GET DAILY SIGNALSPerspective Therapeutics (CATX): Analyst Targets Point to +1,120% Potential Upside From Current Levels
Key Takeaways
- The central target of $10.50 reflects the arithmetic mean of analyst price targets across roughly 11 to 16 covering firms, though the range is extraordinarily wide at approximately $4 to $18.
- Perspective Therapeutics, Inc. (CATX) recently traded near $0.86, meaning the target implies a move of more than 1,100% — a "very large" gap that underscores how far the shares have fallen from their 52-week high of $6.16.
- The company is a clinical-stage radiopharmaceutical developer focused on targeted alpha therapies using lead-212, a differentiated but unproven platform with a long path to regulatory approval.
- Many of the higher targets predate the stock's 2026 collapse, and the most recent revisions have been sharply lower — RBC Capital cut its target to $4 (Hold) and BofA to $5 (Neutral).
- The strongest supports are a deep cash position (roughly $237 million), a "Strong Buy" consensus, and a differentiated oncology pipeline; the biggest risks are heavy dilution, execution uncertainty, and continued negative sentiment.
- Readers can follow the company's Major News and Today's Price Move, review its Forecast, and track upcoming Earnings on additional pages.
Analyst Price Targets and Consensus View
Perspective Therapeutics (CATX), listed on the NYSE American, is a radiopharmaceutical company developing precision targeted alpha therapies (TAT) built around lead-212 and lead-203. Wall Street coverage remains broadly positive on paper, with a "Strong Buy" consensus and an average 12-month price target near $10.50. Independent trackers report figures in the same ballpark — roughly $10.50 to $10.57 — but the low-to-high spread is enormous, from about $4 to $18.
The dispersion is revealing. Recent revisions have cut expectations sharply: RBC Capital downgraded the stock to Hold and trimmed its target from $14 to $4, while BofA maintained a Neutral rating and lowered its target from $6 to $5. Higher targets remain on the books, including Piper Sandler at $14 (reduced from $16), BTIG at $14, BMO Capital at $11, and UBS at $8. Much of this divergence reflects disagreement over lead-212 execution risk, regulatory timelines, and whether the recent financing dilution has permanently reset fair value. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The stock closed near $0.86 on November 9, 2026, near the bottom of a 52-week range of $0.78 to $6.16. Reaching $10.50 would require an advance of roughly 1,120% from current levels — by any standard, a very large move. This is less a forecast of near-term upside and more a reflection of targets that have not yet fully caught up with a brutal selloff: the shares lost about 86% from their January 2026 peak and roughly 58% in October 2026 alone.
The path toward such a target would require the company's lead-212 radiopharmaceutical programs to deliver positive clinical data, secure regulatory clarity, and attract renewed institutional interest — while management preserves its roughly $237 million cash balance through disciplined spending.
What Could Support a Move Toward the Target
- Balance-sheet cushion: With total cash of approximately $237 million (about $2.08 per share) and minimal debt, the company has runway to advance its pipeline.
- Differentiated platform: Lead-212 targeted alpha therapy is viewed as a potentially high-value oncology approach, and several firms cite pipeline assets they consider underappreciated.
- Positive ratings: The majority of covering analysts still hold Buy or Outperform ratings, and the consensus rating remains "Strong Buy."
- Valuation reset: The shares trade well below book value per share (roughly $2.84), leaving room for a re-rating if sentiment stabilizes.
What Could Prevent the Target From Being Reached
- Dilution: A $175 million underwritten offering in early 2026 weighed on the share price, and a sub-$1 stock faces continued risk of further financing overhangs.
- Clinical and regulatory risk: As a clinical-stage company with minimal revenue, approval timelines and data readouts remain uncertain, and analysts have flagged lead-212-specific execution concerns.
- Stale targets: Many price targets were set before the collapse and are being revised lower; the gap between the average target and the price reflects this lag rather than near-term upside.
- Negative momentum: The stock trades far below its 50-day (about $2.34) and 200-day (about $3.50) moving averages, indicating sustained selling pressure.
Technical Levels and Market Structure
Durable levels paint a challenging picture. The stock sits just above its 52-week low near $0.78, which is the immediate support level to watch; a break below could invite further downside. Above the current price, the psychologically important $1.00 mark — recently lost in early November — now acts as near-term resistance. Farther up, the prior trading zone around $2.30–$2.50 aligns with the 50-day moving average, while the 200-day average near $3.50 marks a more substantial recovery hurdle on any path toward the analyst targets. From what I see, monitoring these levels closely helps clarify the near-term technical picture.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though the wide dispersion here signals meaningful disagreement about timing and execution. The next catalyst is the company's estimated earnings report around November 20, 2026, followed by any clinical data updates and potential changes in cash burn guidance. Investors should also watch for further analyst target revisions, additional financing announcements, and any regulatory or pipeline milestones tied to the lead-212 program.
Exploring AI-Driven Trading Tools
I have found AI Daily Buy/Sell Signals from Tickeron useful when reviewing volatile names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and shifting conditions. It serves as a practical complement to fundamental analysis, helping track momentum in fast-moving situations without replacing core research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CATX sees MACD Histogram just turned negative
CATX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 42 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CATX as a result. In 79 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CATX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CATX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where CATX advanced for three days, in 211 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
CATX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.296) is normal, around the industry mean (4.142). P/E Ratio (-0.632) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. CATX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CATX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of therapeutic radioactive isotopes
Industry MedicalNursingServices
Advertisement